NOVARTIS AG
corporate_fare Company Profile
NOVARTIS AG (NYSE:NVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for NVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for NVS spans 6-K, 424B5, FWP, 20-F.
Recent high-impact activity:
- Novartis Beats on Q3 EPS, Raises Core Operating Income Outlook Despite $1.9B Avidity Impairment
- Novartis Q3 Core Beats, FY Core Operating Income Guidance Raised Despite $1.9B Impairment
- Novartis Inks Up to $7.8B RNA Therapeutics Deal With Abogen
- Novartis Scraps ALS Drug After Phase 2 Failure, Adding to Pipeline Setbacks
- Activist Investor Demands Board Shakeup at Novartis After $12B Drug Flop
Financial Snapshot
Short Interest & Short Volume
3.20 days to coverFINRA reported short interest of 5,585,310 shares in NVS as of the October 15, 2026 settlement, a 0.7% decrease from the prior period — about 3.2 days to cover at its recent average daily volume. On October 29, 2026, 55.7% of NVS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.